Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis
Date: 2024-10-01 Authors: April W Armstrong 1, Robert Bissonnette 1, Raj Chovatiya 1, Tina Bhutani 1, Philip M Brown 1, Anna M Tallman 1, Kim A Papp 1 Category: Psoriasis Read more on pubmed
Hand Eczema. Part 2: Prevention, management, and treatment
Date: 2024-9-11 Authors:Robert Bissonnette 1, Tove Agner2, James S Taylor3, Sonja Molin4, Emma Guttman-Yassky5 Category: Eczema Read more on pubmed
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with nonpustular palmoplantar involvement
Date: 2024-08-30 Authors: Mark Lebwohl 1, Michael Bukhalo 2, Linda Stein Gold 3, Brad Glick 4, Mar Llamas-Velasco 5, Samuel Sanchez-Rivera 6, Anqi Pan 7, Tianyu Zhan 7, Leonidas Drogaris 7, Kevin Douglas 7, Greg St John 7, Ramon Espaillat 7, Robert Bissonnette 8 Category: Psoriasis Background: In plaque psoriasis, palmoplantar areas are more difficult to treat. Objective: Evaluate the safety and efficacy of risankizumab (RZB) versus placebo (PBO) for the treatment of palmoplantar psoriasis. Read more on pubmed
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
Date:2024-07-10 Authors:Lisa A Beck 1, Robert Bissonnette2, Mette Deleuran3, Takeshi Nakahara4, Ryszard Galus5, Anna Coleman6, Guy Gherardi7, Jing Xiao8, Robert Dingman8, Christine Xu9, Elena Avetisova8, Ariane Dubost-Brama10, Arsalan Shabbir8 Category: Dermatitis (all types) Importance: Moderate to severe atopic dermatitis (AD) is a chronic inflammatory skin disease that often requires continuous long-term systemic management. Long-term safety and efficacy data for treatment options are critically important. Objective: To assess the safety and efficacy […]
Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials
Date: 2024-05-20 Authors: Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L Category: Dermatitis (all types) Background: Tapinarof cream 1% once daily (QD), a topical aryl hydrocarbon receptor agonist, downregulates pro-inflammatory Th2 cytokines, […]
Adaptive designs in dermatology clinical trials: Current status and future perspectives
Date:2024-04-15 Authors: D. Potvin, P. D’Angelo, S. Bennett, J. Jankicevic, R. Bissonnette Category: Other Abstract: Current drug development strategies present many challenges that can impede drug approval by regulatory agencies. Alternative study models, such as adaptive trial designs, have recently sparked interest, as they provide a flexible and more efficient approach in conducting clinical trials. Adaptive […]
A Phase 1 Study Of The Pharmacokinetics Of Adagrasib In Subjects With Mild, Moderate, Or Severe Hepatic Impairment Compared To Subjects With Normal Hepatic Function.
Date: 2024-03-28 Authors:C. Cilliers1, P. McCloskey1, J. Morin2, J. Tran1; 1Mirati Therapeutics, 2Innovaderm Research. Category: Other Background: This phase I study evaluated the pharmacokinetics of adagrasib in subjects with mild, moderate, or severe hepatic impairment compared to subjects with normal hepatic function. Read more on pubmed
A Phase 1 Study Of The Pharmacokinetics Of Adagrasib In Subjects With Mild, Moderate, Or Severe Renal Impairment Compared To Subjects With Normal Renal Function.
Date:2024-03-28 Authors: C. Cilliers1, P. McCloskey1, J. Morin2, J. Tran1; 1Mirati Therapeutics, 2Innovaderm Research. Category: Other Background: This phase I study evaluated the pharmacokinetics of adagrasib in subjects with mild, moderate, or severe renal impairment compared to subjects with normal renal function. Read more on pubmed
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity
Date: 2024-03-20 Authors: Jonathan I Silverberg 1, Tove Agner2, Keith Baranowski3, Ursula Plohberger3, Henrik Thoning3, Rob Arbuckle4, Laura Grant4, George Skingley4, Robert Bissonnette5 Category: Dermatitis Background: This study aimed to evaluate the psychometric properties of the IGA-CHE for use as an outcome measure in CHE clinical trials and clinical practice. Read more on pubmed
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
Date: 2024-02-27 Authors: David S. Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G. Christensen, Josée Morin, Diane Potvin, Demiana Faltaos, Vanessa Tassell, Hirak Der-Torossian, Richard Chao Category:Other Objectives: Dysregulated signaling by mesenchymal epithelial transition factor (MET) and heightened AXL activation are implicated in the pathogenesis of non-small […]
